Enzo Biochem INC DEF 14A proxy statements
Proxy statements, covering the matters put to shareholders at the annual meeting — board elections, auditor ratification and executive pay.
Enzo Biochem, Inc. shareholders are set to vote on a definitive merger agreement to be acquired by Bethpage Parent, Inc., an affiliate of Battery Ventures, for $0.70 per share in cash, representing a significant premium over recent trading prices.
Enzo Biochem, Inc. has entered into a definitive agreement to be acquired by an affiliate of Battery Ventures for $0.70 per share in cash, totaling approximately $37 million.
Enzo Biochem, Inc. has entered into a definitive agreement to be acquired by Battery Ventures for $0.70 per share in an all-cash transaction valued at approximately $37 million, following a comprehensive strategic review.
Enzo Biochem will hold its 2024 Annual Meeting of Shareholders virtually on January 15, 2025, to vote on director elections, executive compensation, and auditor ratification.